JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 18, 2005; DOI: 10.1124/jpet.105.088674

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.088674v1
315/2/624    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Takashi Okamoto
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, K.
Right arrow Articles by Okamoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, K.
Right arrow Articles by Okamoto, T.


Received for publication May 2, 2005.
Revised July 14, 2005.
Accepted for publication July 15, 2005.

Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor {kappa}B inhibitor parthenolide

Kiyotaka Tanaka 1, Junichi Hasegawa 1, Kaori Asamitsu 1, Takashi Okamoto 1*

1 Nagoya City University Graduate School of Medical Sciences

* Address correspondence to: E-mail: tokamoto{at}med.nagoya-cu.ac.jp

Abstract

The skin photoaging is characterized by keratinocyte hyperproliferation and degradation of collagen fibers, causing skin wrinkling and laxity, and melanocyte proliferation that leads to pigmentation. Ultraviolet (UV) is considered to be a major cause of such skin changes. It is well established that nuclear factor {kappa} B (NF-{kappa}B) is activated upon UV irradiation and induces various genes including interleukin-1 (IL-1), tumor necrosis factor {alpha} (TNF{alpha}), and matrix metalloprotease-1 (MMP-1). It is also known that basic fibroblast growth factor (bFGF) production is induced by UV and promotes the proliferation of skin keratinocytes and melanocytes. We found that UVB, IL-1 and TNF{alpha} induced NF-{kappa}B activation and then produced MMP-1 and bFGF in HaCaT keratinocytes and skin fibroblasts. In this experiment, we examined if parthenolide, an NF-{kappa}B inhibitor, could block the UVB-mediated skin changes. We found that parthenolide could effectively inhibit the gene expression mediated by NF-{kappa}B and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-{kappa}B. We also found that parthenolide could inhibit the UVB-induced proliferation of keratinocytes and melanocytes in the mouse skin. These findings suggest that NF-{kappa}B inhibitors should be useful for the prevention of skin photoaging.


Key words: NF-kB, UV, fibroblast, keratinocyte, melanocyte, skin


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H.-R. Kim, M.-L. Cho, K.-W. Kim, J.-Y. Juhn, S.-Y. Hwang, C.-H. Yoon, S.-H. Park, S.-H. Lee, and H.-Y. Kim
Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-{kappa}B- and p38 MAPK-dependent signalling pathways
Rheumatology, January 1, 2007; 46(1): 57 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
O. Lopez-Franco, P. Hernandez-Vargas, G. Ortiz-Munoz, G. Sanjuan, Y. Suzuki, L. Ortega, J. Blanco, J. Egido, and C. Gomez-Guerrero
Parthenolide Modulates the NF-{kappa}B-Mediated Inflammatory Responses in Experimental Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1864 - 1870.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.